BioLineRx Ltd.

NASDAQ•BLRX

CEO: Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA

セクター: Healthcare

業種: Biotechnology

上場日: 2011-07-27

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

連絡先情報

Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, 7177871, Israel

972-8-642-9100

www.biolinerx.com

時価総額

$15.10M

PER (TTM)

-1.5

24.5

配当利回り

52週高値

$5.40

52週安値

$2.15

52週レンジ

41%

順位65Top 96.0%

1.6

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 1.6 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q1 2026 データ

売上高

$477.00K+0.00%

直近4四半期の推移

EPS

-$0.58+0.00%

直近4四半期の推移

フリーCF

-$2.29M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Comprehensive Loss Significantly Reduced Net comprehensive loss narrowed to $2.0M in 2025 from $60.6M in 2023; R&D expenses were $8.1M.

US Commercial Operations Ceased Sales and marketing expenses dropped to zero in 2025 following Ayrmid out-licensing, refocusing operations to Israel development.

GLIX1 Pipeline Advancement GLIX1 IND cleared by FDA in August 2025; Phase 1/2a study initiation planned for Q1 2026 for GBM treatment.

Cash Position Sufficient Cash and equivalents totaled $3.25M as of December 31, 2025; sufficient to fund requirements into first half of 2027.

リスク要因

Going Concern Uncertainty Remains Accumulated deficit reached $401M by year-end 2025, raising substantial doubt about ability to continue as going concern.

Reliance on Out-Licensing Partners Future revenue and profitability depend heavily on Ayrmid and Gloria successfully commercializing motixafortide globally.

Clinical Trial Success Unpredictable Clinical trial results for GLIX1 and motixafortide are uncertain; failure could materially impact development and financing.

Need for Future Capital Expect continued operating losses, requiring management to seek substantial additional financing through equity or debt offerings.

見通し

GLIX1 Phase 1/2a Study Launch Phase 1/2a study for GLIX1 in GBM expected to initiate in Q1 2026, following IND clearance in August 2025.

Motixafortide Post-Approval Monitoring Five-year long-term follow-up for GENESIS patients post-APHEXDA approval in multiple myeloma is ongoing.

Continued Cost Reduction Focus Operations refocused in Israel post-US shutdown, maintaining a significantly reduced annual cash burn rate moving forward.

同業比較

売上高 (TTM)

EDIT

$38.69M

+8.0%

BLRX

$1.40M

-93.7%

MREO

$500.00K

+0.0%

粗利益率 (最新四半期)

EDIT

82.9%

+2621.3pp

BLRX

80.1%

+0.0pp

CADL

0.0%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
REPL	$711.78M	-2.5	-102.7%	22.9%
ANNX	$562.10M	-4.6	-101.2%	9.7%
CADL	$447.99M	-9.4	-60.4%	0.9%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

16.2%

高成長

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年8月13日

EPS:-$0.15

売上高:$428.50K

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし